Cough Clinical Trial
Official title:
A Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel-designed Phase 2 Clinical Trial to Evaluate the Efficacy and Safety of HS-10383 in Chinese Adult Subjects With Refractory or Unexplained Chronic Cough (RUCC)
Verified date | January 2024 |
Source | Jiangsu Hansoh Pharmaceutical Co., Ltd. |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
This is a multicenter, randomized, double-blind, placebo-controlled, parallel-designed phase 2 clinical trial to evaluate the efficacy, safety and pharmacokinetic (PK) characteristics of HS-10383 in Chinese adult subjects with refractory or unexplained chronic cough (RUCC).
Status | Not yet recruiting |
Enrollment | 276 |
Est. completion date | June 1, 2026 |
Est. primary completion date | September 1, 2025 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 18 Years to 70 Years |
Eligibility | Inclusion Criteria: 1. Subjects should have a full understanding of the study contents, process, and possible adverse reactions, and voluntarily sign the informed consent form; 2. Subjects aged 18-70 years (including the critical value) with RUCC =1 year (diagnosis of RUCC according to the Expert Consensus on Diagnosis and Treatment of Refractory Chronic Cough in China [Released in 2021]); 3. Subjects whose serum pregnancy test is negative in both screening and baseline visits; Exclusion Criteria: 1. Subjects who are diagnosed with chronic obstructive pulmonary disease, bronchiectasis, idiopathic pulmonary fibrosis and other serious lung diseases; 2. Any physiological or mental disease or condition that may increase study risks or interfere with the conduct of the study or affect the ability to complete this study in the opinion of the investigator, such as medical history of depression; 3. Subjects who cannot meet the requirements for piror treatment or who cannot adhere to the concomitant treatment as specified in Section 6.7-Prior/concomitant medications and non-drug treatment. 4. Subjects with positive hepatitis A IgM antibody, hepatitis C antibody (HCVAb), syphilis antibody or human immunodeficiency virus (HIV) antibody at screening visit; subjects with positive hepatitis B surface antigen (HBsAg) at screening (except for quantitative detection result of HBV-DNA is below the lower limit of the detection reference range). 5. Any former smoker with more than 20 packs/year; or have quited smoking for less than 6 months; or subjects who are still smoking (including e-cigarettes); 6. Subjects who have a history of serious drug, food or environmental allergies, or who are known to be allergic to the ingredients of investigational product; 7. History of drug dependence,drug or alcohol abuse in the past year; 8. Female subjects who are pregnant or breastfeeding; 9. Subjects who have previously received anything that may affect drug absorption, including but not limited to: gastrectomy, gastroplasty, any type of weight-loss surgery, vagotomy or enterotomy; 10. Subjects who have been vaccinated within 30 days before screening visit, or have a vaccination plan during the whole study period. |
Country | Name | City | State |
---|---|---|---|
n/a |
Lead Sponsor | Collaborator |
---|---|
Jiangsu Hansoh Pharmaceutical Co., Ltd. |
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | 24-Hour Cough Frequency | Assessed using an ambulatory cough monitor | at Week 4 | |
Secondary | Awake Cough Frequency | Change from baseline in awake cough frequency at week 4; | at Week 4 | |
Secondary | Change from Baseline in Cough Severity Visual Analogue Scale at Week 2 and Week 4; | Assessed by Cough Severity Visual Analogue Scale [VAS] by the participant on a 100 mm visual analog scale where higher scores indicate greater severity. | at Week 2 and Week 4 | |
Secondary | Change from Baseline in the Leicester Cough Questionnaire (LCQ) Total Score at Week 2 and Week 4. | The LCQ is a patient-reported quality of life (QOL) measure of chronic cough,the higher scores mean a better outcome. | at Week 2 and Week 4 |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT00116337 -
Spinal Cord Stimulation to Restore Cough
|
N/A | |
Not yet recruiting |
NCT04064333 -
Slow-Stream Expiratory Muscle Strength Training for Veterans With Dysphagia Living in Long-term Care
|
N/A | |
Recruiting |
NCT02482818 -
Efficacy of Pregabalin on Chronic Cough
|
Phase 1/Phase 2 | |
Terminated |
NCT02269761 -
Chest Ultrasound of ER Patients With Cough or SOB
|
||
Active, not recruiting |
NCT02065440 -
The Effect of Ebastine/Pseudoephedrine on Subacute Cough
|
N/A | |
Completed |
NCT01071161 -
The Effect of Azithromycin in Patients With Chronic Obstructive Pulmonary Disease (COPD) and Chronic Productive Cough
|
Phase 3 | |
Completed |
NCT00353951 -
An Observational Study of Cough / Lower Respiratory Tract Infection (LRTI) in Primary Care
|
N/A | |
Terminated |
NCT00668317 -
Bronchial Hyper-responsiveness in Reflux Cough
|
Phase 3 | |
Completed |
NCT00127686 -
Effect of Honey and Dextromethorphan on Nocturnal Cough and Sleep
|
Phase 1 | |
Completed |
NCT00287339 -
The Utility of Nexium in Chronic Cough and Reflux Disease
|
Phase 4 | |
Recruiting |
NCT05115097 -
AI Evaluation of COVID-19 Sounds (AI-EChOS)
|
||
Recruiting |
NCT04457011 -
Efficacy and Safety of Susu Zhike Granules for Treating Acute Cough Due to Common Cold With Cold-cough Syndrome in Children
|
Phase 2 | |
Recruiting |
NCT05042063 -
Acoustic Cough Monitoring for the Management of Patients With Known Respiratory Disease
|
||
Recruiting |
NCT03922373 -
A Study of Benzonatate Soft Capsule in Chinese Healthy Subjects
|
Phase 1 | |
Completed |
NCT05812209 -
Stellate Ganglion Block to Treat Long COVID 19 Case Series
|
||
Recruiting |
NCT04767074 -
A Non-pharmacological Cough Control Therapy
|
N/A | |
Recruiting |
NCT05570539 -
Assessment of the Pharmacokinetics of BLU-5937 Extended Release Prototypes and a BLU-5937 Immediate Release Reference Formulation
|
Phase 1 | |
Completed |
NCT03999203 -
A Cross-sectional Study to Measure Cough in Severe Asthma
|
N/A | |
Active, not recruiting |
NCT05479929 -
Work of Breathing Assessment in Triage Scale
|
||
Recruiting |
NCT02495571 -
Assessment of Voluntary and Reflex Cough in Patients With ALS
|
N/A |